talmapimod

Talmapimod is an orally bioavailable, small-molecule inhibitor of p38 mitogen-activated protein kinase (MAPK), specifically targeting the p38 alpha isoform with high potency. Developed as a first-generation oral p38 MAP kinase inhibitor by Scios, talmapimod was investigated for its immunomodulating, anti-inflammatory, and antineoplastic activities. By inhibiting phosphorylation of p38 MAPK—a serine/threonine protein kinase involved in cellular responses to stress and inflammation—talmapimod may induce tumor cell apoptosis, inhibit tumor proliferation and angiogenesis, and modulate inflammatory pathways. It was primarily developed for conditions such as rheumatoid arthritis, multiple myeloma, and myelodysplastic syndromes[1][2][3][4][5].

Other names

talmapimod